Literature DB >> 10086224

Understanding airway disease in infants.

J D Finder1.   

Abstract

Large airway diseases manifest in ways distinct from those of small airway diseases. Noisy breathing that begins early in life suggests a congenital lesion of the large airways. The findings of elevated respiratory rate, in conjunction with subcostal retractions, hyperinflation to percussion, and musical wheezes, are diagnostic of small airway obstruction. Differentiating large from small airway disease is crucial, because each disease has a distinct diagnosis, and treatment of the 2 disease types can be quite different. When these principles are applied to a patient with wheezing or other signs of airway compromise, it becomes fairly easy to differentiate large from small airway disease. The treatment of patients with large airway disease can be substantially different from that of patients with small airway disease. Being able to differentiate the two is critically important. With the use of the history, physical examination, and radiographic evaluations described earlier, nearly every patient can be given an accurate diagnosis and treated appropriately.

Entities:  

Mesh:

Year:  1999        PMID: 10086224     DOI: 10.1016/s0045-9380(99)80040-1

Source DB:  PubMed          Journal:  Curr Probl Pediatr        ISSN: 0045-9380


  2 in total

1.  Bedside clinical assessment predicts recurrence after hospitalization due to viral lower respiratory tract infection in young children.

Authors:  Maria Arroyo; Kyle P Salka; Geovanny F Perez; Carlos E Rodriguez-Martinez; Jose A Castro-Rodriguez; Gustavo Nino
Journal:  J Investig Med       Date:  2019-12-05       Impact factor: 2.895

2.  Phenotypical Sub-setting of the First Episode of Severe Viral Respiratory Infection Based on Clinical Assessment and Underlying Airway Disease: A Pilot Study.

Authors:  Maria Arroyo; Kyle Salka; Geovanny F Perez; Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Maria J Gutierrez; Gustavo Nino
Journal:  Front Pediatr       Date:  2020-04-02       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.